AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2019
Jan 18, 2019
33422_dirs_2019-01-18_c693ac46-967d-4efe-9edf-5e3f6c0bdd5c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2019-01-16
Reporting Person: SHULMAN STEPHEN (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-16 | Stock option (right to buy) | $4.72 | A | 25000 | Acquired | 2029-01-16 | Common stock (25000) | Direct |
Footnotes
F1: The options vest 100% on January 16, 2020.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21